FMP

FMP

Enter

SNDX - Syndax Pharmace...

photo-url-https://images.financialmodelingprep.com/symbol/SNDX.png

Syndax Pharmaceuticals, Inc.

SNDX

NASDAQ

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

14.94 USD

-0.62 (-4.15%)

Historical Prices

From:

To:

We are unable to load the chart at this time.

fmp-logo

About

ceo

Mr. Michael A. Metzger M.B.A.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with Nation...

CIK

0001395937

ISIN

US87164F1057

CUSIP

87164F105

Address

35 Gatehouse Drive

Phone

781 419 1400

Country

US

Employee

184

IPO Date

Mar 2, 2016

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

SNDX Financial Summary

CIK

0001395937

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

87164F105

ISIN

US87164F1057

Country

US

Price

14.94

Beta

0.92

Volume Avg.

1.45M

Market Cap

1.28B

Shares

-

52-Week

14.57-25.34

DCF

4.17

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-4.1

P/B

-

Website

https://www.syndax.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest SNDX News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep